ENDO 2025 at a glance

Get ready for ENDO 2025, where Endocrinology scientific insights and AI come together. This overview highlights the key presentations and cross-cutting AI-driven breakthroughs shaping tomorrow’s practice.

📅 Build your schedule around the topics that interest you. 📥 Download the ENDO 2025_Preview_by_LucidQuest

Dive deeper

Key Topics From ENDO 2025 Scientific Presentations

Pituitary Disease 🧠

Surveys show sleep disruption, anxiety, and fatigue are common after pituitary injury.
Early, specialized follow-up—especially in post-TBI and MEN1—improves QoL and hormone recovery.

Adrenal Disorders 🛡️

Crinecerfont (CRF1 antagonist) and Lu AG13909 (anti-ACTH mAb) cut androgen excess and lower steroid doses in congenital adrenal hyperplasia.
Obesity, smoking, and dysglycemia emerge as modifiable risks for adrenal adenomas.

Thyroid Health 🦋

Familial non-medullary thyroid cancer significantly worsens day-to-day wellbeing.
TgAb-positive differentiated thyroid cancer carries higher persistence/recurrence risk.
Plasma-exchange shows life-saving impact in thyroid storm.

Diabetes Care 🍏

CGM adoption in uninsured communities drives sharp A1c declines.
PCOS + impaired glucose tolerance heightens pre-eclampsia and lowers birthweight, underscoring early metabolic screening in pregnancy.

Bone & Oncology 🦴

Stopping denosumab nearly triples skeletal-event rates; post-bariatric denosumab preserves bone micro-architecture.
Post-thyroidectomy hypoparathyroidism raises renal and cardiac risks.

CardioMetabolic Risk ❤️

High LDL remains a major burden across Latin America.
CETP inhibitors and dual GLP-1/SGLT2 strategies improve lipids and liver fibrosis, but must be matched to local access gaps.

Rare Endocrine 📊

ΔBMD% at the hip is a strong fracture surrogate, potentially speeding osteoporosis drug trials.
Early switch from denosumab to zoledronic acid shows modest bone loss with no clinical fractures.

Artificial Intelligence and Machine Learning at ENDO 2025

AI in pituitary care

CatBoost predicts somatostatin-analog resistance in acromegaly (AUROC 0.90), guiding early therapy shifts.

AI in thyroid care

Image-based models flag thyroid eye disease and post-cancer breast-risk with higher accuracy than traditional scoring.

AI in metabolic care

Radar-based waist-to-hip sensors and serum-proteomic signatures forecast insulin-resistance responses; ML beats manual dosing in pediatric hyperthyroidism.

AI in NAFLD screening

Ultrasound + clinical-AI triage fast-tracks NASH diagnosis, easing specialty bottlenecks.

📅 Build your schedule around the topics that interest you.

📥 Download the ENDO 2025_Preview_by_LucidQuest